SCHEMBL9912436

SCHEMBL9912436

Cc1ccc2ncsc2c1Cl

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 1/20 0.33
AXL P30530 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
ABL1 P00519 1/20 0.32
DYRK1A Q13627 1/20 0.32
PTPN11 Q06124 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
MAPK1 P28482 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
HKDC1 Q2TB90 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069128 0.79 ALDH1A1 (0.35) ALDH1A1HSD17B10AXLMKNK1MKNK2
SCHEMBL8306186 0.79 ALDH1A1 (0.35) ALDH1A1HSD17B10ABL1DYRK1AMAPK1
SCHEMBL22025577 0.76 KDM4E (0.33) ALDH1A1HSD17B10ABL1MAPK1SMN1; SMN2
SCHEMBL20855206 0.76 ALDH1A1 (0.33) ALDH1A1HSD17B10ABL1MAPK1SMN1; SMN2
SCHEMBL12121766 0.76 ABL1 (0.34) ALDH1A1HSD17B10ABL1DYRK1AMAPK1
SCHEMBL6068320 0.76 CCNE1 (0.37) ALDH1A1HSD17B10AXLMKNK1MKNK2
SCHEMBL18876099 0.76 P2RX7 (0.34) ALDH1A1HSD17B10AXLMKNK1MKNK2
SCHEMBL21631702 0.76 ALDH1A1 (0.33) ALDH1A1HSD17B10AXLMKNK1MKNK2
SCHEMBL29309229 0.76 ALDH1A1 (0.33) ALDH1A1HSD17B10AXLMKNK1MKNK2
SCHEMBL6788818 0.76 DYRK1A (0.39) ALDH1A1HSD17B10AXLMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-16 US disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 PTPN1, PTPN9, PTPN7 ALDH1A1 3810/4885HSD17B10 2830/4885AXL 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.